600196 复星医药
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额2,423,9525,213,2274,476,9813,414,2174,217,571
投资活动产生之现金流量净额(4,428,098)(2,145,766)(3,613,323)(3,819,290)(4,064,038)
筹资活动产生之现金流量净额2,676,004(3,244,090)(1,002,586)(1,336,250)4,428,475
汇率变动对现金及现金等价物的影响(222,601)(176,811)27,98973,645128,342
现金及现金等价物净增加/(减少)449,257(353,440)(110,939)(1,667,678)4,710,350
期初现金及现金等价物余额9,038,0109,391,4509,502,38911,170,0676,459,717
期末现金及现金等价物余额9,487,2679,038,0109,391,4509,502,38911,170,067